Cargando…
Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration
Tauopathies are a group of neurodegenerative diseases characterized by the alteration/aggregation of TAU protein, for which there is still no effective treatment. Therefore, new pharmacological targets are being sought, such as elements of the endocannabinoid system (ECS). We analysed the occurrence...
Autores principales: | Galán-Ganga, M., Rodríguez-Cueto, C., Merchán-Rubira, J., Hernández, F., Ávila, J., Posada-Ayala, M., Lanciego, J. L., Luengo, E., Lopez, M. G., Rábano, A., Fernández-Ruiz, J., Lastres-Becker, I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130522/ https://www.ncbi.nlm.nih.gov/pubmed/34001284 http://dx.doi.org/10.1186/s40478-021-01196-5 |
Ejemplares similares
-
Aging, NRF2, and TAU: A Perfect Match for Neurodegeneration?
por: Brackhan, Mirjam, et al.
Publicado: (2023) -
Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism
por: Sierra, Salvador, et al.
Publicado: (2014) -
Effects of pro‐inflammatory cytokines on cannabinoid CB
(1) and CB
(2) receptors in immune cells
por: Jean‐Gilles, L., et al.
Publicado: (2015) -
Cannabinoid CB(1) and CB(2) Receptor Signaling and Bias
por: Ibsen, Mikkel Søes, et al.
Publicado: (2017) -
The Structure–Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation
por: Bow, Eric W., et al.
Publicado: (2016)